Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Jun 3, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with colon adenocarcinoma, a type of colorectal cancer, who still have traces of cancer after initial treatment. The researchers want to see how effective a combination of two medications, called TAS-102 and irinotecan, is for patients whose blood tests show the presence of circulating tumor DNA (ctDNA), indicating that some cancer cells may still be in the body. This trial is open to patients aged 18 and older who have been treated for Stage II, III, or IV colon cancer and have tested positive for ctDNA after receiving chemotherapy.

To participate, patients need to meet certain criteria, such as having undergone successful surgery to remove their cancer, being able to take medications by mouth, and having a life expectancy of at least three months. Participants can expect to take the medications for at least three months and will be closely monitored for their health and any side effects. It's important to note that women who can become pregnant and men must use effective birth control during the study due to potential risks to a developing fetus. This trial is currently recruiting, and interested patients should discuss their eligibility with their healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients must have histologically or cytologically confirmed adenocarcinoma of the colon (high rectal cancer is eligible if resected and no radiation needed). Other histologies which are treated per NCCN guidelines for adjuvant colon cancer are eligible.
• • 2. Must have Stage II, Stage III, or Stage IV colorectal cancer after curative intent resection eligible for adjuvant doublet chemotherapy for at least 3 months.
• • 3. Must have ctDNA positive assay (tested by Signatera MRD assay) after at least 3 months of perioperative chemotherapy
• • 4. Age ≥ 18 years
• • 5. Performance status: ECOG performance status ≤2
• • 6. Life expectancy of greater than 3 months
• 7. Adequate organ and marrow function as defined below:
• • 1. leukocytesL ≥ 3,000/mcL
• • 2. absolute neutrophil count: ≥ 1,500/mcL
• • 3. platelets: ≥ 80,000/mcl
• • 4. total bilirubin: within normal institutional limits
• • 5. AST(SGOT)/ALT(SPGT): ≤ 3 X institutional upper limit of normal or ≤ 5 X if liver metastases are present
• • 6. creatinine: \<1.5 X ULN
• • 8. The effects of TAS-102 on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because topoisomerase inhibitors are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• a. A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:
• • Has not undergone a hysterectomy or bilateral oophorectomy; or
• • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).
• • 9. Ability to swallow tablets
• • 10. Ability to understand and the willingness to sign a written informed consent.
• Exclusion Criteria:
• • 1. Patients who have had major surgery within 4 weeks, or chemotherapy or radiotherapy within 2 weeks prior to Cycle 1 Day 1
• • 2. All toxicities attributed to prior anti-cancer therapy other than alopecia must have resolved to grade 1 or baseline
• • 3. Patients may not be receiving any other investigational agents.
• • 4. Patients with known metastases.
• • 5. History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102, irinotecan or other agents used in study.
• • 6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• • 7. Prior treatment with TAS-102 at any time or irinotecan within 90 days from enrollment.
• • 8. History of another primary cancer within the last 3 years with the exception of non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ.
• • 9. Inability to comply with study and follow-up procedures as judged by the Investigator
• • 10. Patients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants. -